يعرض 1 - 20 نتائج من 127 نتيجة بحث عن '"Luhn, Kerstin"', وقت الاستعلام: 0.63s تنقيح النتائج
  1. 1
    Academic Journal

    المساهمون: Churchill Hospital Oxford Centre for Haematology, University of Oxford, CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P)), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg, Les Hôpitaux Universitaires de Strasbourg (HUS)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Hôpital de Hautepierre Strasbourg, Centre Hospitalier Universitaire Rennes, Centre d'Investigation Clinique Rennes (CIC), Université de Rennes (UR)-Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Pontchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor Créteil, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), London School of Hygiene and Tropical Medicine (LSHTM), Janssen Vaccines & Prevention Leiden, This study was sponsored by Janssen Vaccines & Prevention B.V. The EBL1001 study was sponsored by Crucell Holland (now Janssen Vaccines & Prevention B.V.) and received funding from the Innovative Medicines Initiative (IMI) under Grant Agreement No. 115854 (EBOVAC1, this joint undertaking received support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations). EBL1002 was supported by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health (NIAID/NIH, Contract HHSN272200800056C), and Janssen Vaccines & Prevention B.V. EBL1003 and EBL1004 were supported by the IMI 2 Joint Undertaking (IMI2JU) under Grant Agreements No. 115854 (EBOVAC1), No. 115861 (EBOVAC2), No. 115850 (EBOMAN Project via the Janssen Ebola Vaccine Program), and No. 115847 (EBODAC Project via the Janssen Ebola Vaccine Program), Janssen Vaccines & Prevention B.V., the European Union’s Horizon 2020 research and innovation program (which provided funding via IMI2JU), the European Federation of Pharmaceutical Industries and Associations (which provided funding via IMI2JU), and the NIAID/NIH (Contract HHSN272200800056C to the Janssen Filovirus Project). EBL2001 was sponsored by Janssen Vaccines & Prevention B.V. and received support from the IMI2JU under Grant Agreement No. 115861 (EBOVAC2) as part of the IMI Ebola+ program, this joint undertaking received support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. EBL2002 was supported by Janssen Vaccines & Prevention B.V. and the IMI2JU under Grant Agreement No. 115861 (EBOVAC2) as part of the IMI Ebola+ program, and the National Institute for Health Research Oxford Biomedical Research Centre. EBL3002 and EBL3003 were funded by Janssen Vaccines & Prevention B.V. and the Biomedical Advanced Research and Development Authority (Contract HHSO100201500008C).

    المصدر: EISSN: 2076-393X ; Vaccines ; https://hal.science/hal-04478273 ; Vaccines, 2024, Vaccines, 12 (2), pp.210-210. ⟨10.3390/vaccines12020210⟩

    Relation: info:eu-repo/semantics/altIdentifier/pmid/38400193; PUBMED: 38400193

  2. 2
    Academic Journal

    وصف الملف: text

    Relation: https://researchonline.lshtm.ac.uk/id/eprint/4673458/2/vaccines-12-00828-1.pdf; https://researchonline.lshtm.ac.uk/id/eprint/4673458/1/vaccines-3050943-supplementary.pdf; Choi, Edward Man-Lik ; Kasonia, Kambale; Kavunga-Membo, Hugo; Mukadi-Bamuleka, Daniel; Soumah, Aboubacar; Mossoko, Zephyrin; Edwards, Tansy ; Tetsa-Tata, Darius; Makarimi, Rockyath; Toure, Oumar; +19 more. Mambula, Grace; Brindle, Hannah; Camacho, Anton; Connor, Nicholas E ; Mukadi, Pierre; McLean, Chelsea; Keshinro, Babajide; Gaddah, Auguste; Robinson, Cynthia; Luhn, Kerstin; Foster, Julie; Roberts, Chrissy H ; Johnson, John Emery; Imbault, Nathalie; Bausch, Daniel G; Grais, Rebecca F; Watson-Jones, Deborah; Muyembe-Tamfum, Jean Jacques; Tujiokowe Study Consortium; (2024) Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo. Vaccines, 12 (8). p. 828. ISSN 2076-393X DOI: https://doi.org/10.3390/vaccines12080828

  3. 3
    Academic Journal
  4. 4
  5. 5
  6. 6
    Academic Journal

    وصف الملف: text

    Relation: https://researchonline.lshtm.ac.uk/id/eprint/4671457/1/1-s2.0-S0264410X23012574-main.pdf; https://researchonline.lshtm.ac.uk/id/eprint/4671457/8/1-s2.0-S0264410X23012574-mmc1.pdf; Man-Lik Choi, Edward; Abu-Baker Mustapher, Ggayi; Omosa-Manyonyi, Gloria; Foster, Julie; Anywaine, Zacchaeus; Musila Mutua, Michael; Ayieko, Philip ; Vudriko, Tobias; Ann Mwangi, Irene; Njie, Yusupha; +17 more. Ayoub, Kakande; Mundia Muriuki, Moses; Kasonia, Kambale; Edward Connor, Nicholas; Florence, Nambaziira; Manno, Daniela ; Katwere, Michael; McLean, Chelsea; Gaddah, Auguste; Luhn, Kerstin; Lowe, Brett; Greenwood, Brian ; Robinson, Cynthia; Anzala, Omu; Kaleebu, Pontiano ; Watson-Jones, Deborah; EBL2010 Study Team; (2023) Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda. Vaccine, 41 (50). pp. 7573-7580. ISSN 0264-410X DOI: https://doi.org/10.1016/j.vaccine.2023.10.055

  7. 7
    Academic Journal

    وصف الملف: text

    Relation: https://researchonline.lshtm.ac.uk/id/eprint/4671367/1/Choi-etal-2023-Safety-and-immunogenicity-of-the-two-dose-heterologous-Ad26.ZEBOV-and-MVA-BN-Filo-Ebola-vaccine-regimen-in-infants.pdf; Choi, Edward Man-Lik ; Lacarra, Boris; Afolabi, Muhammed O ; Ale, Boni Maxime; Baiden, Frank; Bétard, Christine; Foster, Julie; Hamzé, Benjamin; Schwimmer, Christine; Manno, Daniela; +30 more. D'Ortenzio, Eric; Ishola, David; Keita, Cheick Mohamed; Keshinro, Babajide; Njie, Yusupha; van Dijck, Wim; Gaddah, Auguste; Anumendem, Dickson; Lowe, Brett; Vatrinet, Renaud; Lawal, Bolarinde Joseph; Otieno, Godfrey T; Samai, Mohamed; Deen, Gibrilla Fadlu; Swaray, Ibrahim Bob; Kamara, Abu Bakarr; Kamara, Michael Morlai; Diagne, Mame Aminata; Kowuor, Dickens; McLean, Chelsea; Leigh, Bailah; Beavogui, Abdoul Habib; Leyssen, Maarten; Luhn, Kerstin; Robinson, Cynthia; Douoguih, Macaya; Greenwood, Brian ; Thiébaut, Rodolphe; Watson-Jones, Deborah; EBOVAC-3/EBL2005 Study Team; (2023) Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone. The Lancet Global health, 11 (11). e1743-e1752. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-109X(23)00410-2

  8. 8
  9. 9
    Academic Journal
  10. 10
  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal

    وصف الملف: text

    Relation: https://researchonline.lshtm.ac.uk/id/eprint/4668097/1/Wagstaffe_etal_2022_NK-cell-subset-redistribution-and.pdf; Wagstaffe, Helen R; Anzala, Omu; Kibuuka, Hannah; Anywaine, Zacchaeus ; Sirima, Sodiomon B; Thiébaut, Rodolphe; Richert, Laura; Levy, Yves; Lacabaratz, Christine; Bockstal, Viki; +3 more. Luhn, Kerstin; Douoguih, Macaya; Goodier, Martin R ; (2022) NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans. Vaccines, 10 (6). p. 884. ISSN 2076-393X DOI: https://doi.org/10.3390/vaccines10060884

  15. 15
    Academic Journal

    وصف الملف: text

    Relation: https://researchonline.lshtm.ac.uk/id/eprint/4664990/1/e055596.full.pdf; Watson-Jones, Deborah; Kavunga-Membo, Hugo; Grais, Rebecca F; Ahuka, Steve; Roberts, Natalie; Edmunds, W John ; Choi, Edward M ; Roberts, Chrissy H ; Edwards, Tansy ; Camacho, Anton; +9 more. Lees, Shelley ; Leyssen, Maarten; Spiessens, Bart; Luhn, Kerstin; Douoguih, Macaya; Hatchett, Richard; Bausch, Daniel G; Muyembe, Jean-Jacques; DRC-EB-001 protocol writing team; (2022) Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo. BMJ open, 12 (3). e055596-. ISSN 2044-6055 DOI: https://doi.org/10.1136/bmjopen-2021-055596

  16. 16
  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
    Academic Journal
  20. 20
    Academic Journal